Motegrity Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Motegrity Indications
Indications
Motegrity Dosage and Administration
Adult
Children
Renal Impairment
No dosage adjustment is required for patients with mild and moderate renal impairment (CrCl at least 30 mL/min, as determined from a 24-hour urine collection in the clinical trial).
Motegrity is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. A decreased dosage is recommended in patients with severe renal impairment (CrCl <30 mL/min, as determined from a 24-hour urine collection in the clinical trial).
Avoid Motegrity in patients with ESRD requiring dialysis.
Motegrity Contraindications
Contraindications
Motegrity Boxed Warnings
Not Applicable
Motegrity Warnings/Precautions
Warnings/Precautions
Motegrity Pharmacokinetics
Absorption
Following a single oral dose of 2 mg prucalopride in healthy subjects, peak plasma concentrations are observed within 2–3 hours after administration.
Absolute oral bioavailability: >90%.
Distribution
Prucalopride has a steady-state volume of distribution (Vss) of 567 L after intravenous administration.
Plasma protein bound: ~30%.
Elimination
Renal (84.2%), fecal (13.3%).
Motegrity Interactions
Motegrity Adverse Reactions
Adverse Reactions
Motegrity Clinical Trials
Motegrity Note
Not Applicable
Motegrity Patient Counseling
Cost Savings Program
Patient Assistance Program is available here.
Images
